ADAR

Double-stranded RNA-specific adenosine deaminase is an enzyme that in humans is encoded by the ADAR gene (which stands for adenosine deaminase acting on RNA).[5][6]

For other uses, see Adar (disambiguation).
ADAR
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesADAR, ADAR1, AGS6, DRADA, DSH, DSRAD, G1P1, IFI-4, IFI4, K88DSRBP, P136, adenosine deaminase, RNA-specific, adenosine deaminase, RNA specific, adenosine deaminase RNA specific
External IDsOMIM: 146920 MGI: 1889575 HomoloGene: 9281 GeneCards: ADAR
Gene location (Human)
Chr.Chromosome 1 (human)[1]
Band1q21.3Start154,582,057 bp[1]
End154,628,013 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

103

56417

Ensembl

ENSG00000160710

ENSMUSG00000027951

UniProt

P55265

Q99MU3

RefSeq (mRNA)

NM_001038587
NM_001146296
NM_019655
NM_001357958

RefSeq (protein)

NP_001020278
NP_001102
NP_001180424
NP_056655
NP_056656

NP_001033676
NP_001139768
NP_062629
NP_001344887

Location (UCSC)Chr 1: 154.58 – 154.63 MbChr 3: 89.72 – 89.75 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Adenosine deaminases acting on RNA (ADAR) are enzymes responsible for binding to double stranded RNA (dsRNA) and converting adenosine (A) to inosine (I) by deamination.[7] ADAR protein is a RNA-binding protein, which functions in RNA-editing through post-transcriptional modification of mRNA transcripts by changing the nucleotide content of the RNA.[8] The conversion from A to I in the RNA disrupt the normal A:U pairing which makes the RNA unstable. Inosine is structurally similar to that of guanine (G) which leads to I to cytosine (C) binding. Inosine typically mimicks guanosine during translation.[9] Codon changes can arise from editing which may lead to changes in the coding sequences for proteins and their functions.[10] Most editing sites are found in noncoding regions of RNA such as untranslated regions (UTRs), Alu elements, and long interspersed nuclear element (LINEs).[11] Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria, as well as Aicardi–Goutières syndrome.[12] Alternate transcriptional splice variants, encoding different isoforms, have been characterized.[8] ADAR also impacts the transcriptome in editing-independent ways, likely by interfering with other RNA-binding proteins.[13]

Discovery

Adenosine deaminase acting on RNA (ADAR) and its gene were first discovered accidentally in 1987 as a result of research by Brenda Bass and Harold Weintraub.[14] These researchers were using antisense RNA inhibition to determine which genes play a key role in the development of Xenopus laevis embryos. Previous research on Xenopus oocytes had been successful. However, when Bass and Weintraub applied identical protocols to Xenopus embryos, they were unable to determine the embryo’s developmental genes. In an attempt to understand why the method was unsuccessful, they began comparing duplex RNA in both oocytes and embryos. This led them to discover that a developmentally regulated activity denatures RNA:RNA hybrids in embryos.

In 1988, Richard Wagner et al. further studied the activity occurring on Xenopus embryos.[15] They determined that a protein was responsible for the unwinding of RNA due to the absence of activity after proteinase treatment. It was also shown that this protein is specific for double stranded RNA, or dsRNA, and does not require ATP. Additionally, it became evident that the protein’s activity on dsRNA modifies it beyond a point of rehybridization, but does not fully denature it. Finally, the researchers determined that this unwinding is due to the deamination of adenosine residues to inosine. This modification results in mismatched base-pairing between inosine and uridine, leading to the destabilization and unwinding of dsRNA.

Function and origin

ADARs acting on RNA is one of the most common forms of RNA editing, and has both selective and non-selective activity.[16] ADAR is able to both modify and regulate the output of gene product, as inosine is interpreted by the cell to be guanosine. ADAR has also been determined to change the functionality of small RNA molecules. Recently, ADARs have also been discovered as a splicing regulator with their editing capability or RNA binding function.[17][18] It is believed that ADAR evolved from ADAT (Adenosine Deaminase Acting on tRNA), a critical protein present in all eukaryotes, early in the metazoan period through the addition of a dsRNA binding domain. This likely occurred in the lineage which leads to the crown Metazoa when a duplicate ADAT gene was coupled to a gene encoding at least one double stranded RNA binding. The ADAR family of genes has been largely conserved over the history of its existence. This, along with its presence in the majority of modern phyla, indicates that RNA editing is an essential regulatory gene for metazoan organisms. ADAR has not been discovered in a variety of non-metazoan eukaryotes, such as plants, fungi and choanoflagellates.


Types

In mammals, there are three types of ADARs, 1, 2 and 3.[19] ADAR1 and ADAR2 are found in many tissues in the body while ADAR3 is only found in the brain.[10] ADAR1 and ADAR2 are known to be catalytically active while ADAR3 is thought to be inactive.[10] ADAR1 has two known isoforms known as ADAR1p150 and ADAR1p110. ADAR1p110 is usually only found in the nucleus while ADAR1p150 shuffles between the nucleus to the cytoplasm and is mostly present in the cytoplasm.[19] Although ADAR1 and ADAR2 share many common functional domains as well as commonality in terms of expression pattern, structure of protein and requirements of substrates having double stranded RNA structures, they differ in their editing activity.[20]

Catalytic activity

Biochemical reaction

ADARs catalyze the reaction from A to I by hydrolytic deamination.[7] It does this by the use of an activated water molecule for a nucelophilic attack. It is done by the addition of water to carbon 6 and removal of ammonia with a hydrated intermediate.

  • scheme of adenosine conversion to inosine via ADAR

Active site

In humans, the enzyme's active site has 2-3 amino-terminal dsRNA binding domains (dsRBDs) and one carboxy terminal catalytic deaminase domain.[19] In the dsRBD domain there is a conserved α-β-β-β-α configuration present.[10] ADAR1 contains two areas for binding Z-DNA known as Zα and Zβ. ADAR2 and ADAR3 have an arginine rich single stranded RNA (ssRNA) binding domain. A crystal structure of ADAR2 has been solved.[19] In the enzyme active site, there is a glutamic acid residue(E396) that hydrogen bonds to a water. There is a histidine (H394) and two cysteine restudies (C451 and C516) that coordinates a zinc ion. The zinc activates the water molecule for the nucelophilic hydrolytic deamination. Within the catalytic core there is an inositol hexakisphosphate (IP6), which stabilizes arginine and lysine residues.

Dimerization

It has been found in mammals that the conversion from A to I requires homodimerization of ADAR1 and ADAR2, but not ADAR3.[10] In vivo studies have not yet been conclusive if RNA binding is required for dimerization. A study with ADAR1 and 2 mutants which were not able to bind to dsRNA were still able to dimerize, showing they may bind based on protein-protein interactions[10][21]

Model organisms

Model organisms have been used in the study of ADAR function. A conditional knockout mouse line, called Adartm1a(EUCOMM)Wtsi[22][23] was generated as part of the International Knockout Mouse Consortium program — a high-throughput mutagenesis project to generate and distribute animal models of disease to interested scientists[24][25][26] Male and female animals underwent a standardized phenotypic screen to determine the effects of deletion.[27][28] Twenty five tests were carried out on mutant mice and two significant abnormalities were observed.[6] Few homozygous mutant embryos were identified during gestation, and none survived until weaning. The remaining tests were carried out on heterozygous mutant adult mice and no abnormalities were observed in these animals.[27]

Role in disease

Aicardi–Goutières syndrome and Bilateral Striatal Necrosis/Dystonia

ADAR1 is one of multiple genes which can contribute to Aicardi–Goutières syndrome when mutated.[12] This is a genetic inflammatory disease primarily affecting the skin and the brain. The inflammation is caused by incorrect activation of interferon inducible genes such as those activated to fight off viral infections. Mutation and loss of function of ADAR1 prevents destabilization of double stranded RNA (dsRNA) and the body mistakes this for viral RNA resulting in an autoimmune response.[29] The phenotype in Adar knock-out mice is rescued by the p150 form of ADAR1 containing the Zα domain that binds specifically to the left-handed double-stranded conformation found in Z-DNA and Z-RNA, but not by the p110 isoform that lacks this domain.[30] In humans, the P193A mutation in the Zα domain is causal for Aicardi–Goutières syndrome [12] and for the more severe phenotype found in Bilateral Striatal Necrosis/Dystonia.[31] The findings establish a biological role for the left-handed Z-DNA conformation.[32]

HIV

Research has shown that ADAR1 can be both beneficial and a hindrance in a cells ability to fight off HIV infection. Expression levels of the ADAR1 protein have shown to be elevated during HIV infection and it has been suggested that it is responsible for A to G mutations in the HIV genome, inhibiting replication.[33] The authors of this study also suggest that mutation of the HIV genome by ADAR1 might in some cases lead to beneficial viral mutations which could contribute to drug resistance.

Hepatocellular carcinoma

Studies of samples from patients with hepatocellular carcinoma (HCC) have shown that ADAR1 is frequently upregulated and ADAR2 is frequently downregulated in the disease. It has been suggested that this is responsible for the disrupted A to I editing pattern seen in HCC and that ADAR1 acts as an oncogene in this context whilst ADAR2 has tumor suppressor activities.[34] The imbalance of ADAR expression could change the frequency of A to I transitions in the protein coding region of genes, resulting in mutated proteins which drive the disease. The dysregulation of ADAR1 and ADAR2 could be used as a possible poor prognostic marker.

Melanoma

In contrast to hepatocellular carcinoma, several research studies have indicated that loss of ADAR1 contributes to melanoma growth and metastasis. It is known that ADAR can act on microRNA and affect its biogenesis, stability and/or its binding target.[35] It has been suggested that ADAR1 is downregulated by cAMP- response element binding protein (CREB), limiting its ability to act on miRNA.[36] One such example is miR-455-5p which is edited by ADAR1. When ADAR is downregulated by CREB the unedited miR-455-5p downregulates a tumor suppressor protein called CPEB1, contributing to melanoma progression in an in vivo model.[36]

Dyschromatosis symmetrica hereditaria (DSH1)

A Gly1007Arg mutation in ADAR1, as well as other truncated versions, have been implicated as a cause in some cases of DSH1.[37] This is a disease characterized by hyperpigmentation in the hands and feet and can occur in Japanese and Chinese families.

Viral activity

Antiviral

ADAR1 is an interferon ( IFN )-inducible protein (one released by a cell in response to a pathogen or virus), so it would make sense that it would assist with a cell’s immune pathway. This seems to be true for the HCV replicon, Lymphocytic choriomeningitis LCMV, and polyomavirus[38]

Proviral

ADAR1 is known to be proviral in other circumstances. ADAR1’s A to I editing has been found in many viruses including measles virus,[39][40] influenza virus,[41] lymphocytic choriomeningitis virus,[42] polyomavirus,[43] hepatitis delta virus,[44] and hepatitis C virus.[45] Although ADAR1 has been seen in other viruses, it has only been studied extensively in a few; one of those is measles virus (MV). Research done on MV has shown that ADAR1 enhances viral replication. This is done through two different mechanisms: RNA editing and inhibition of dsRNA-activated protein kinase (PKR).[38] Specifically, viruses are thought to use ADAR1 as a positive replication factor by selectively suppressing dsRNA-dependent and antiviral pathways.[46]

gollark: > subpoening the vpn company for the encryption algorityhmsI'm pretty sure this is not actually a thing. But they totally could (and probably do often) keep logs.
gollark: I see.
gollark: Aren't the scooters quite heavy? Can you do that?
gollark: No.
gollark: My alt.

See also

References
  1. GRCh38: Ensembl release 89: ENSG00000160710 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000027951 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K (November 1994). "Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing". Proceedings of the National Academy of Sciences of the United States of America. 91 (24): 11457–61. doi:10.1073/pnas.91.24.11457. PMC 45250. PMID 7972084.
  6. "Entrez Gene: ADAR Adenosine Deaminase Acting on RNA".
  7. Samuel CE (2012). Adenosine deaminases acting on RNA (ADARs) and A-to-I editing. Heidelberg: Springer. ISBN 978-3-642-22800-1.
  8. "ADAR". NCBI. U.S. National Library of Medicine.
  9. Licht K, Hartl M, Amman F, Anrather D, Janisiw MP, Jantsch MF (November 2018). "Inosine induces context-dependent recoding and translational stalling". Nucleic Acids Research. 47 (1): 3–14. doi:10.1093/nar/gky1163. PMC 6326813. PMID 30462291.
  10. Nishikura K (7 June 2010). "Functions and regulation of RNA editing by ADAR deaminases". Annual Review of Biochemistry. 79 (1): 321–49. doi:10.1146/annurev-biochem-060208-105251. PMC 2953425. PMID 20192758.
  11. Tajaddod M, Jantsch MF, Licht K (March 2016). "The dynamic epitranscriptome: A to I editing modulates genetic information". Chromosoma. 125 (1): 51–63. doi:10.1007/s00412-015-0526-9. PMC 4761006. PMID 26148686.
  12. Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. (November 2012). "Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature". Nature Genetics. 44 (11): 1243–8. doi:10.1038/ng.2414. PMC 4154508. PMID 23001123.
  13. Licht K, Jantsch MF (November 2017). "The Other Face of an Editor: ADAR1 Functions in Editing-Independent Ways". BioEssays. 39 (11): 1700129. doi:10.1002/bies.201700129. PMID 28960389.
  14. Samuel CE (March 2011). "Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral". Virology. 411 (2): 180–93. doi:10.1016/j.virol.2010.12.004. PMC 3057271. PMID 21211811.
  15. Wagner RW, Smith JE, Cooperman BS, Nishikura K (1989). "A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs". Proceedings of the National Academy of Sciences of the United States of America. 86 (8): 2647–51. doi:10.1073/pnas.86.8.2647. PMC 286974. PMID 2704740.
  16. Grice LF, Degnan BM (2015-01-29). "The origin of the ADAR gene family and animal RNA editing". BMC Evolutionary Biology. 15 (1): 4. doi:10.1186/s12862-015-0279-3. PMC 4323055. PMID 25630791.
  17. Tang SJ, Shen H, An O, et al. (2020-02-07). "Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development". Nat Commun. 11: 799. doi:10.1038/s41467-020-14621-5. PMC 7005744. PMID 32034135.
  18. Hsiao YE, Bahn JH, Yang Y, et al. (2018). "RNA editing in nascent RNA affects pre-mRNA splicing". Genome Res. 28 (6): 812–823. doi:10.1101/gr.231209.117. PMC 5991522. PMID 29724793.
  19. Savva YA, Rieder LE, Reenan RA (2012). "The ADAR protein family". Genome Biology. 13 (12): 252. doi:10.1186/gb-2012-13-12-252. PMC 3580408. PMID 23273215.
  20. Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Burnashev N, Feldmeyer D, Sprengel R, Seeburg PH (July 2000). "Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2". Nature. 406 (6791): 78–81. doi:10.1038/35017558. PMID 10894545.
  21. Cho DS, Yang W, Lee JT, Shiekhattar R, Murray JM, Nishikura K (May 2003). "Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA". The Journal of Biological Chemistry. 278 (19): 17093–102. doi:10.1074/jbc.M213127200. PMID 12618436.
  22. "International Knockout Mouse Consortium".
  23. "Mouse Genome Informatics".
  24. Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas M, Harrow J, Cox T, Jackson D, Severin J, Biggs P, Fu J, Nefedov M, de Jong PJ, Stewart AF, Bradley A (June 2011). "A conditional knockout resource for the genome-wide study of mouse gene function". Nature. 474 (7351): 337–42. doi:10.1038/nature10163. PMC 3572410. PMID 21677750.
  25. Dolgin E (June 2011). "Mouse library set to be knockout". Nature. 474 (7351): 262–3. doi:10.1038/474262a. PMID 21677718.
  26. Collins FS, Rossant J, Wurst W (January 2007). "A mouse for all reasons". Cell. 128 (1): 9–13. doi:10.1016/j.cell.2006.12.018. PMID 17218247.
  27. GERDIN, AK (September 2010). "The Sanger Mouse Genetics Programme: high throughput characterisation of knockout mice". Acta Ophthalmologica. 88: 0. doi:10.1111/j.1755-3768.2010.4142.x.
  28. van der Weyden L, White JK, Adams DJ, Logan DW (2011). "The mouse genetics toolkit: revealing function and mechanism". Genome Biology. 12 (6): 224. doi:10.1186/gb-2011-12-6-224. PMC 3218837. PMID 21722353.
  29. Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, Hartner JC, Li JB, Seeburg PH, Walkley CR (September 2015). "RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself". Science. 349 (6252): 1115–20. doi:10.1126/science.aac7049. PMC 5444807. PMID 26275108.
  30. Ward SV, George CX, Welcha MJ, Lioua LY, Hahma B, Lewickia H, Torrea JC, Samuel CE, Oldstone MB (January 2011). "RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis". PNAS. 108 (1): 331–336. doi:10.1073/pnas.1017241108. PMC 3017198. PMID 21173229.
  31. Livingston JH, Lin JP, Dale RC, Gill D, Brogan P, Munnich A, et al. (February 2014). "A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1". Journal of Medical Genetics. 51 (2): 76–82. doi:10.1136/jmedgenet-2013-102038. PMID 24262145.
  32. Herbert A (July 2019). "Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zα domain of the double-stranded RNA editing enzyme ADAR". European Journal of Human Genetics. 8: 114–117. doi:10.1038/s41431-019-0458-6. PMC 6906422. PMID 31320745.
  33. Weiden MD, Hoshino S, Levy DN, Li Y, Kumar R, Burke SA, Dawson R, Hioe CE, Borkowsky W, Rom WN, Hoshino Y (2014). "Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages". PLOS ONE. 9 (10): e108476. doi:10.1371/journal.pone.0108476. PMC 4182706. PMID 25272020.
  34. Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L (May 2014). "A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma". Gut. 63 (5): 832–43. doi:10.1136/gutjnl-2012-304037. PMC 3995272. PMID 23766440.
  35. Heale BS, Keegan LP, McGurk L, Michlewski G, Brindle J, Stanton CM, Caceres JF, O'Connell MA (October 2009). "Editing independent effects of ADARs on the miRNA/siRNA pathways". The EMBO Journal. 28 (20): 3145–56. doi:10.1038/emboj.2009.244. PMC 2735678. PMID 19713932.
  36. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M (March 2015). "Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis". Nature Cell Biology. 17 (3): 311–21. doi:10.1038/ncb3110. PMC 4344852. PMID 25686251.
  37. Tojo K, Sekijima Y, Suzuki T, Suzuki N, Tomita Y, Yoshida K, Hashimoto T, Ikeda S (September 2006). "Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation". Movement Disorders. 21 (9): 1510–3. doi:10.1002/mds.21011. PMID 16817193.
  38. Gélinas JF, Clerzius G, Shaw E, Gatignol A (September 2011). "Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase". Journal of Virology. 85 (17): 8460–6. doi:10.1128/JVI.00240-11. PMC 3165853. PMID 21490091.
  39. Baczko K, Lampe J, Liebert UG, Brinckmann U, ter Meulen V, Pardowitz I, Budka H, Cosby SL, Isserte S, Rima BK (November 1993). "Clonal expansion of hypermutated measles virus in a SSPE brain". Virology. 197 (1): 188–95. doi:10.1006/viro.1993.1579. PMID 8212553.
  40. Cattaneo (21 October 1988). "Biased hypermutation and other genetic changes in defective measles viruses in human brain infections". Cell. 55 (2): 255–65. doi:10.1016/0092-8674(88)90048-7. PMC 7126660. PMID 3167982.
  41. Tenoever BR, Ng SL, Chua MA, McWhirter SM, García-Sastre A, Maniatis T (March 2007). "Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity". Science. 315 (5816): 1274–8. doi:10.1126/science.1136567. PMID 17332413.
  42. Zahn RC, Schelp I, Utermöhlen O, von Laer D (January 2007). "A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus". Journal of Virology. 81 (2): 457–64. doi:10.1128/jvi.00067-06. PMC 1797460. PMID 17020943.
  43. Kumar (15 April 1997). "Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts". Proc Natl Acad Sci USA. 94 (8): 3542–7. doi:10.1073/pnas.94.8.3542. PMC 20475. PMID 9108012.
  44. Luo GX, Chao M, Hsieh SY, Sureau C, Nishikura K, Taylor J (1990). "A specific base transition occurs on replicating hepatitis delta virus RNA". Journal of Virology. 64 (3): 1021–7. PMC 249212. PMID 2304136.
  45. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM (2005). "New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1". Journal of Virology. 79 (10): 6291–8. doi:10.1128/JVI.79.10.6291-6298.2005. PMC 1091666. PMID 15858013.
  46. Toth AM, Li Z, Cattaneo R, Samuel CE (October 2009). "RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR". The Journal of Biological Chemistry. 284 (43): 29350–6. doi:10.1074/jbc.M109.045146. PMC 2785566. PMID 19710021.

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.